Cytokinetics Reports Results From Phase 2 Trial Of Omecamtiv Mecarbil In Japense Patients With Heart Failure; Co. Eligible To Earn $10M Milestone Payment From Amgen Upon First Patient Dosing In Phase 3 Trial